Stable angina is the most common type of coronary artery disease, and the main pathogenesis is an imbalance of blood and oxygen supply to the myocardium. Patients with stable angina should be evaluated in detail based on their clinical, non-invasive and invasive tests, and risk stratification should be performed on this basis. Patients with stable angina should undergo lifestyle changes, control risk factors, and select and optimize pharmacological therapy as well as non-pharmacological therapy such as revascularization according to the patient’s risk level. Pharmacological treatment is the basis of treatment for stable angina pectoris. Specifically, for stable angina, standard pharmacological therapy includes the use of aspirin, statins, angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers. Studies have shown no significant reduction in the incidence of death or nonfatal infarction in patients with stable angina with pharmacologic therapy compared with revascularization. For low-risk patients who are asymptomatic, have only objective ischemic basis or have mild symptoms, pharmacological treatment should be tried first, while those who are ineffective in pharmacological treatment or have frequent symptoms should be treated with interventional therapy on top of pharmacological treatment to effectively control angina symptoms and improve the quality of life. Drug therapy, interventional therapy and surgical procedures should complement each other rather than contradict or conflict with each other. Evidence-based treatment with reference to guidelines and patient-specific analysis is the basic strategy for the treatment of stable angina pectoris.